Zhangzhou Pientzehuang Pharmaceutical., Ltd
SSE:600436.SS
200.9 (CNY) • At close June 17, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 10,787.863 | 10,058.497 | 8,694.002 | 8,021.55 | 6,510.782 | 5,722.273 | 4,766.157 | 3,713.954 | 2,308.954 | 1,885.675 | 1,453.87 | 1,395.869 | 1,171.154 | 1,021.566 | 867.315 | 694.75 | 649.743 | 593.069 | 522.205 | 418.821 | 253.486 | 213.594 | 212.033 | 193.894 | 183.922 |
| Cost of Revenue
| 6,177.643 | 5,355.27 | 4,725.854 | 3,952.98 | 3,570.558 | 3,190.943 | 2,744.358 | 2,107.193 | 1,178.821 | 999.306 | 728.158 | 634.151 | 551.328 | 556.39 | 533.076 | 430.401 | 408.222 | 375.03 | 332.337 | 215.124 | 83.026 | 70.424 | 74.492 | 70.884 | 65.558 |
| Gross Profit
| 4,610.22 | 4,703.228 | 3,968.147 | 4,068.571 | 2,940.224 | 2,531.33 | 2,021.799 | 1,606.761 | 1,130.133 | 886.368 | 725.711 | 761.718 | 619.826 | 465.176 | 334.239 | 264.349 | 241.522 | 218.039 | 189.868 | 203.697 | 170.46 | 143.17 | 137.541 | 123.01 | 118.364 |
| Gross Profit Ratio
| 0.427 | 0.468 | 0.456 | 0.507 | 0.452 | 0.442 | 0.424 | 0.433 | 0.489 | 0.47 | 0.499 | 0.546 | 0.529 | 0.455 | 0.385 | 0.38 | 0.372 | 0.368 | 0.364 | 0.486 | 0.672 | 0.67 | 0.649 | 0.634 | 0.644 |
| Reseach & Development Expenses
| 258.158 | 232.354 | 230.034 | 199.511 | 97.552 | 119.432 | 100.814 | 139.809 | 66.945 | 49.612 | 45.179 | 46.992 | 23.198 | 14.918 | 8.593 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 97.232 | 109.917 | 51.024 | 64.746 | 71.408 | 47.391 | 51.527 | -31.176 | 29.092 | 27.394 | 18.38 | 22.246 | 20.099 | 19.09 | 16.784 | 54.792 | 44.135 | 39.01 | 37.743 | 42.15 | 71.326 | 31.354 | 23.433 | 18.135 | 20.481 |
| Selling & Marketing Expenses
| 328.488 | 590.857 | 483.359 | 650.574 | 646.779 | 523.063 | 392.069 | 403.53 | 274.835 | 166.436 | 128.832 | 117.811 | 113.002 | 70.261 | 59.504 | 51.026 | 67.107 | 45.1 | 32.287 | 36.156 | 22.421 | 28.332 | 23.348 | 20.461 | 10.935 |
| SG&A
| 425.72 | 1,075.189 | 534.382 | 715.32 | 718.187 | 570.454 | 443.596 | 372.354 | 303.926 | 193.83 | 147.213 | 140.056 | 133.101 | 89.35 | 76.288 | 105.818 | 111.241 | 84.11 | 70.029 | 78.307 | 93.748 | 59.687 | 46.781 | 38.596 | 31.416 |
| Other Expenses
| 354.226 | 2.011 | 341.104 | 376.261 | 293.702 | 258.149 | 7.463 | -5.832 | 4.727 | 11.181 | 9.876 | 13.98 | 25.729 | 0.364 | 2.193 | 0.866 | 0.469 | 2.437 | 0.251 | 2.401 | 1.904 | 2.366 | 0.727 | 0.911 | -2.878 |
| Operating Expenses
| 1,038.103 | 1,309.554 | 1,105.521 | 1,291.092 | 1,109.44 | 948.035 | 769.202 | 703.612 | 522.985 | 364.246 | 286.631 | 261.301 | 220.474 | 158.872 | 132.164 | 111.284 | 114.982 | 88.238 | 74.028 | 83.464 | 97.417 | 61.628 | 47.968 | 41.887 | 33.632 |
| Operating Income
| 3,572.117 | 3,393.674 | 2,975.714 | 2,874.495 | 1,977.089 | 1,638.148 | 1,320.028 | 947.394 | 608.48 | 541.594 | 508.151 | 496.682 | 389.99 | 305.336 | 231.011 | 152.622 | 168.013 | 147.154 | 126.526 | 132.104 | 77.074 | 89.433 | 88.881 | 80.967 | 84.058 |
| Operating Income Ratio
| 0.331 | 0.337 | 0.342 | 0.358 | 0.304 | 0.286 | 0.277 | 0.255 | 0.264 | 0.287 | 0.35 | 0.356 | 0.333 | 0.299 | 0.266 | 0.22 | 0.259 | 0.248 | 0.242 | 0.315 | 0.304 | 0.419 | 0.419 | 0.418 | 0.457 |
| Total Other Income Expenses Net
| -33.376 | -24.762 | 2.022 | -5.472 | 1.809 | 6.445 | 7.463 | -5.832 | 4.243 | 8.108 | 9.451 | 12.852 | 23.091 | -0.466 | 1.307 | 0.285 | 41.792 | 18.392 | 0.169 | 12.274 | 1.202 | 1.244 | -0.101 | -0.378 | -3.008 |
| Income Before Tax
| 3,538.741 | 3,368.913 | 2,977.735 | 2,869.023 | 1,978.898 | 1,644.593 | 1,327.492 | 941.562 | 609.215 | 549.702 | 517.601 | 509.534 | 415.259 | 304.87 | 232.318 | 153.194 | 168.331 | 148.192 | 126.64 | 133.506 | 78.276 | 90.677 | 88.781 | 80.589 | 81.049 |
| Income Before Tax Ratio
| 0.328 | 0.335 | 0.343 | 0.358 | 0.304 | 0.287 | 0.279 | 0.254 | 0.264 | 0.292 | 0.356 | 0.365 | 0.355 | 0.298 | 0.268 | 0.221 | 0.259 | 0.25 | 0.243 | 0.319 | 0.309 | 0.425 | 0.419 | 0.416 | 0.441 |
| Income Tax Expense
| 543.214 | 517.773 | 454.758 | 405.002 | 289.543 | 257.658 | 198.765 | 161.136 | 102.397 | 86.362 | 79.711 | 78.436 | 64.678 | 48.328 | 37.618 | 22.94 | 26.666 | 51.792 | 42.835 | 46.326 | 36.379 | 30.102 | 29.992 | 28.426 | 30.996 |
| Net Income
| 2,977.002 | 2,797.352 | 2,472.345 | 2,431.9 | 1,671.519 | 1,374.377 | 1,142.933 | 807.019 | 536.132 | 466.677 | 438.829 | 429.768 | 348.53 | 254.868 | 194.132 | 129.663 | 140.87 | 95.189 | 81.908 | 86.398 | 41.774 | 60.478 | 58.788 | 52.162 | 50.053 |
| Net Income Ratio
| 0.276 | 0.278 | 0.284 | 0.303 | 0.257 | 0.24 | 0.24 | 0.217 | 0.232 | 0.247 | 0.302 | 0.308 | 0.298 | 0.249 | 0.224 | 0.187 | 0.217 | 0.161 | 0.157 | 0.206 | 0.165 | 0.283 | 0.277 | 0.269 | 0.272 |
| EPS
| 4.93 | 4.64 | 4.1 | 4.03 | 2.77 | 2.28 | 1.89 | 1.34 | 0.89 | 0.77 | 0.73 | 0.73 | 0.6 | 0.44 | 0.34 | 0.22 | 0.24 | 0.16 | 0.14 | 0.12 | 0.056 | 0.081 | 0.11 | 0.09 | 0.086 |
| EPS Diluted
| 4.93 | 4.64 | 4.1 | 4.03 | 2.77 | 2.28 | 1.89 | 1.34 | 0.89 | 0.77 | 0.73 | 0.73 | 0.6 | 0.44 | 0.34 | 0.22 | 0.24 | 0.16 | 0.14 | 0.12 | 0.056 | 0.081 | 0.11 | 0.09 | 0.086 |
| EBITDA
| 3,670.961 | 3,575.635 | 3,124.651 | 3,048.345 | 2,074.431 | 1,731.524 | 1,338.622 | 1,018.742 | 684.854 | 598.478 | 568.077 | 557.937 | 453.631 | 325.834 | 253.237 | 168.905 | 184.929 | 143.816 | 136.88 | 142.677 | 87.079 | 98.993 | 98.274 | 88.688 | 81.951 |
| EBITDA Ratio
| 0.34 | 0.355 | 0.359 | 0.38 | 0.319 | 0.303 | 0.281 | 0.274 | 0.297 | 0.317 | 0.391 | 0.4 | 0.387 | 0.319 | 0.292 | 0.243 | 0.285 | 0.242 | 0.262 | 0.341 | 0.344 | 0.463 | 0.463 | 0.457 | 0.446 |